Phase 1 trial of CAR T-cell therapy for lymphoma

At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Catherine Bollard, MBChB, MD, FRACP, FRCPA, from Children’s National Medical Center, Washington, DC, discusses the initial analysis of a phase 1 dose-escalation study of activated autologous CD30-specific chimeric antigen receptors (CAR) T cells infused in patients with relapsed or refractory CD30-positive Hodgkin lymphoma or non-Hodgkin lymphoma.

Share this video  
Similar topics